JP2007512237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007512237A5 JP2007512237A5 JP2006536948A JP2006536948A JP2007512237A5 JP 2007512237 A5 JP2007512237 A5 JP 2007512237A5 JP 2006536948 A JP2006536948 A JP 2006536948A JP 2006536948 A JP2006536948 A JP 2006536948A JP 2007512237 A5 JP2007512237 A5 JP 2007512237A5
- Authority
- JP
- Japan
- Prior art keywords
- ibandronate sodium
- ray
- crystalline form
- reflection
- sodium crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60402604P | 2004-08-23 | 2004-08-23 | |
| US69086705P | 2005-06-16 | 2005-06-16 | |
| PCT/US2005/030500 WO2006024024A2 (en) | 2004-08-23 | 2005-08-23 | Solid and crystalline ibandronate sodium and processes for preparation thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007512237A JP2007512237A (ja) | 2007-05-17 |
| JP2007512237A5 true JP2007512237A5 (enExample) | 2008-02-14 |
| JP4559431B2 JP4559431B2 (ja) | 2010-10-06 |
Family
ID=35968334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536948A Expired - Lifetime JP4559431B2 (ja) | 2004-08-23 | 2005-08-23 | 固体及び結晶イバンドロネートナトリウム及びその調製方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7563918B2 (enExample) |
| EP (2) | EP1930011B1 (enExample) |
| JP (1) | JP4559431B2 (enExample) |
| KR (2) | KR20070043043A (enExample) |
| CN (1) | CN101022812A (enExample) |
| AT (2) | ATE520406T1 (enExample) |
| CA (1) | CA2576659A1 (enExample) |
| DE (2) | DE202005021414U1 (enExample) |
| ES (1) | ES2358269T3 (enExample) |
| IL (1) | IL181298A (enExample) |
| PT (2) | PT1930011E (enExample) |
| WO (1) | WO2006024024A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045637A1 (es) | 2003-09-12 | 2005-11-02 | Amgen Inc | Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio |
| LT2662380T (lt) * | 2005-02-01 | 2019-03-12 | Atnahs Pharma Uk Limited | Ibandronato polimorfo a medicininis panaudojimas |
| EP2610261A1 (en) | 2005-02-01 | 2013-07-03 | F. Hoffmann-La Roche AG | Ibandronate polymorph B |
| WO2007074475A2 (en) * | 2005-12-27 | 2007-07-05 | Natco Pharma Limited | Novel polymorphic forms of ibandronate |
| WO2008014510A2 (en) * | 2006-07-28 | 2008-01-31 | Dr. Reddy's Laboratories Limited | Crystalline form a of ibandronic acid and process for the preparation |
| WO2008060609A1 (en) * | 2006-11-16 | 2008-05-22 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ibandronate sodium |
| CA2570949A1 (en) * | 2006-12-12 | 2008-06-12 | Apotex Pharmachem Inc. | Ibandronate sodium propylene glycol solvate and processes for the preparation thereof |
| EP2144919B1 (en) | 2007-04-11 | 2015-12-02 | F. Hoffmann-La Roche AG | Multi step synthesis of ibandronate |
| AU2008242788A1 (en) * | 2007-04-19 | 2008-10-30 | Dr. Reddy's Laboratories Ltd. | Ibandronate sodium polymorphs |
| WO2009020483A1 (en) * | 2007-08-09 | 2009-02-12 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ibandronate sodium |
| EP2128166A1 (en) | 2008-05-20 | 2009-12-02 | Chemo Ibérica, S.A. | Polymorphic forms of Ibandronate sodium and processes for preparation thereof |
| WO2009053445A2 (en) * | 2007-10-26 | 2009-04-30 | Chemo Ibérica, S.A. | Polymorphic forms of ibandronate sodium and processes for preparation thereof |
| US20090118239A1 (en) * | 2007-11-05 | 2009-05-07 | Teva Pharmaceutical Industries Ltd. | Amorphous and crystalline forms of ibandronate disodium |
| EP2180003A1 (en) | 2008-10-21 | 2010-04-28 | Zentiva, k.s. | Preparation of ibandronate trisodium |
| MX339194B (es) | 2009-02-13 | 2016-05-16 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma. |
| US9192316B2 (en) | 2009-05-15 | 2015-11-24 | Nox Medical | Systems and methods using flexible capacitive electrodes for measuring biosignals |
| WO2011016738A1 (en) | 2009-08-05 | 2011-02-10 | Zaklady Farmaceutyczne Polpharma Sa | A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate |
| EP3351249A1 (en) | 2010-01-27 | 2018-07-25 | VIIV Healthcare Company | Antiviral therapy |
| US9059532B2 (en) | 2010-06-25 | 2015-06-16 | Nox Medical | Biometric belt connector |
| KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| WO2013179305A1 (en) * | 2012-06-01 | 2013-12-05 | Hetero Research Foundation | Ibandronate sodium solid dispersion |
| WO2014170909A2 (en) | 2013-04-01 | 2014-10-23 | Hetero Research Foundation | Process for pomalidomide |
| US10588550B2 (en) | 2013-11-06 | 2020-03-17 | Nox Medical | Method, apparatus, and system for measuring respiratory effort |
| TWI665190B (zh) | 2013-11-15 | 2019-07-11 | 阿克比治療有限公司 | ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途 |
| US10869619B2 (en) | 2016-08-19 | 2020-12-22 | Nox Medical | Method, apparatus, and system for measuring respiratory effort of a subject |
| US11896386B2 (en) | 2017-06-02 | 2024-02-13 | Nox Medical Ehf | Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study |
| US11602282B2 (en) | 2017-09-08 | 2023-03-14 | Nox Medical Ehf | System and method for non-invasively determining an internal component of respiratory effort |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| JP2639721B2 (ja) | 1988-12-27 | 1997-08-13 | 富士重工業株式会社 | 内燃機関の燃焼室 |
| US5652227A (en) * | 1995-01-30 | 1997-07-29 | Teronen; Olli Pekka | Inhibition of the degradation of connective tissue matrix protein components in mammals |
| DE19637890A1 (de) * | 1996-09-17 | 1998-03-19 | Max Planck Gesellschaft | Biphosphonat-Liposomen |
| DE19828450A1 (de) * | 1998-06-26 | 1999-12-30 | Hassan Jomaa | Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien |
| EP0998933A1 (de) * | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation |
| EP0998932A1 (de) * | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung |
| EP1178810B8 (en) * | 1999-05-21 | 2005-07-27 | Novartis AG | Use of bisphosphonic acids for treating angiogenesis |
| US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| KR100492110B1 (ko) * | 2000-05-05 | 2005-06-02 | 에프. 호프만-라 로슈 아게 | 비스포스폰산 또는 그의 염을 포함하는 피하 투여용겔-유사 약학 조성물 |
| DK1296689T3 (da) * | 2000-06-20 | 2005-11-28 | Novartis Ag | Fremgangsmåde til indgivelse af bisphosphonater |
| GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| JP2002332235A (ja) * | 2001-02-01 | 2002-11-22 | Riderway Corp | 骨疾患治療用液体医薬組成物 |
| ITMI20020908A1 (it) | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione di sodio alendronato |
| BR0308901A (pt) * | 2002-05-10 | 2005-01-04 | Hoffmann La Roche | ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose |
| WO2003099992A2 (en) * | 2002-05-17 | 2003-12-04 | Wyeth | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
| ES2530791T3 (es) * | 2002-12-20 | 2015-03-05 | Hoffmann La Roche | Formulación de ibandronato de altas dosis |
| US7723542B2 (en) * | 2003-12-23 | 2010-05-25 | Trifarma S.P.A. | Process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof |
| MX2007000087A (es) * | 2004-06-23 | 2007-11-06 | Teva Pharma | Acido ibandronico solido y cristalino. |
| EP2610261A1 (en) | 2005-02-01 | 2013-07-03 | F. Hoffmann-La Roche AG | Ibandronate polymorph B |
| LT2662380T (lt) | 2005-02-01 | 2019-03-12 | Atnahs Pharma Uk Limited | Ibandronato polimorfo a medicininis panaudojimas |
| WO2007074475A2 (en) | 2005-12-27 | 2007-07-05 | Natco Pharma Limited | Novel polymorphic forms of ibandronate |
-
2005
- 2005-08-23 ES ES05791142T patent/ES2358269T3/es not_active Expired - Lifetime
- 2005-08-23 JP JP2006536948A patent/JP4559431B2/ja not_active Expired - Lifetime
- 2005-08-23 EP EP08002626A patent/EP1930011B1/en not_active Expired - Lifetime
- 2005-08-23 AT AT08002626T patent/ATE520406T1/de not_active IP Right Cessation
- 2005-08-23 AT AT05791142T patent/ATE495747T1/de not_active IP Right Cessation
- 2005-08-23 KR KR1020077005922A patent/KR20070043043A/ko not_active Ceased
- 2005-08-23 CA CA002576659A patent/CA2576659A1/en not_active Abandoned
- 2005-08-23 PT PT08002626T patent/PT1930011E/pt unknown
- 2005-08-23 WO PCT/US2005/030500 patent/WO2006024024A2/en not_active Ceased
- 2005-08-23 CN CNA2005800285039A patent/CN101022812A/zh active Pending
- 2005-08-23 EP EP05791142A patent/EP1713489B1/en not_active Revoked
- 2005-08-23 PT PT05791142T patent/PT1713489E/pt unknown
- 2005-08-23 DE DE202005021414U patent/DE202005021414U1/de not_active Expired - Lifetime
- 2005-08-23 KR KR1020097022363A patent/KR20090120011A/ko not_active Ceased
- 2005-08-23 DE DE602005025977T patent/DE602005025977D1/de not_active Expired - Lifetime
-
2006
- 2006-12-22 US US11/644,568 patent/US7563918B2/en not_active Expired - Fee Related
-
2007
- 2007-02-13 IL IL181298A patent/IL181298A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3470063T3 (fi) | Lääkekoostumuksia cftr-välitteisten sairauksien hoitoon | |
| JP2011527299A5 (enExample) | ||
| JP2009235100A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2023002516A5 (enExample) | ||
| JP2013545785A5 (enExample) | ||
| HRP20171175T1 (hr) | Novi triciklički spojevi | |
| RU2013109393A (ru) | Безилатная соль ингибитора втк | |
| FI2629097T1 (fi) | Nrf2-seulontatestejä ja niihin liittyviä menetelmiä ja koostumuksia | |
| HRP20140666T1 (hr) | Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora | |
| JP2013509429A5 (enExample) | ||
| JP2014523445A5 (enExample) | ||
| JP2010513478A5 (enExample) | ||
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| HRP20150584T1 (hr) | Soli i polimorfi tetraciklinskog spoja | |
| JP2011500621A5 (enExample) | ||
| HRP20130026T1 (hr) | Kristalni oblik posakonazola | |
| HRP20140004T1 (hr) | Novi spojevi 951: bifeniloksipropanska kiselina kao crth2 modulator i intermedijeri | |
| NZ592383A (en) | Pharmaceutical composition of a potent hcv inhibitor for oral administration | |
| IL181298A0 (en) | Solid and crystalline ibandronate sodium and processes for preparation thereof | |
| PH12013501727A1 (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
| HRP20150062T1 (hr) | Farmaceutski pripravak koji sadrži optički aktivan spoj koji sadrži agonist receptora trombopoietina i njegov međuprodukt | |
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| JP2019151627A5 (enExample) | ||
| ME02480B (me) | Optimizirana sinteza čistih, nepolimorfnih, kristalnih žučnih kiselina sa određenom veličinom čestica |